Prevention and management of adverse events of novel agents in multiple myeloma: A consensus of the European Myeloma Network

Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hajek R, Mohty M, Cavo M, Dimopoulos MA, San-Miguel JF, Terpos E, Zweegman S, Garderet L, Mateos MV, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, Van De Donk NWCJ, Waage A, Beksac M, Mellqvist UH, Engelhardt M, Caers J, Driessen C, Blade J, Sonneveld P (2018)

Publication Type: Journal article, Review article

Publication year: 2018

Journal

Book Volume: 32

Pages Range: 1542-1560

Journal Issue: 7

DOI: 10.1038/s41375-018-0040-1

Abstract

During the last few years, several new drugs have been introduced for treatment of patients with multiple myeloma, which have significantly improved the treatment outcome. All of these novel substances differ at least in part in their mode of action from similar drugs of the same drug class, or are representatives of new drug classes, and as such present with very specific side effect profiles. In this review, we summarize these adverse events, provide information on their prevention, and give practical guidance for monitoring of patients and for management of adverse events.

Involved external institutions

Katholieke Universiteit Leuven (KUL) / Catholic University of Leuven Belgium (BE) Centre Hospitalier Régional Universitaire de Lille (CHRU de Lille) France (FR) Universitätsklinikum Würzburg Germany (DE) University of Turin / Università degli Studi di Torino (UNITO) Italy (IT) St. Olavs University Hospital / St. Olavs Hospital Universitetssykehuset i Trondheim Norway (NO) Ankara University / Ankara Üniversitesi Turkey (TR) Sahlgrenska University Hospital / Sahlgrenska Universitetssjukhuset Sweden (SE) Albert-Ludwigs-Universität Freiburg Germany (DE) Centre Hospitalier Universitaire de Liège (CHU Liège) Belgium (BE) Kantonsspital St.Gallen Switzerland (CH) Hospital Clínic de Barcelona Spain (ES) Erasmus University Medical Center (MC) Netherlands (NL) Université de Nantes France (FR) Université Fédérale de Toulouse Midi-Pyrénées France (FR) University of Ostrava / Ostravská univerzita v Ostravě Czech Republic (CZ) University of Paris 6 - Pierre et Marie Curie / Université Paris VI Pierre et Marie Curie (UPMC) France (FR) University of Bologna / Università di Bologna Italy (IT) National and Kapodistrian University of Athens Greece (GR) Clínica Universidad de Navarra Spain (ES) Vrije Universiteit Amsterdam (VU) / University Amsterdam Netherlands (NL) Instituto de Investigación Biomédica de Salamanca (IBSAL) Spain (ES) University of Leeds United Kingdom (GB) Centre hospitalier universitaire de Poitiers (CHU de Poitiers) France (FR) Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg Germany (DE) Newcastle University United Kingdom (GB) The Institute of Cancer Research (ICR) United Kingdom (GB) Eberhard Karls Universität Tübingen Germany (DE)

How to cite

APA:

Ludwig, H., Delforge, M., Facon, T., Einsele, H., Gay, F., Moreau, P.,... Sonneveld, P. (2018). Prevention and management of adverse events of novel agents in multiple myeloma: A consensus of the European Myeloma Network. Leukemia, 32(7), 1542-1560. https://doi.org/10.1038/s41375-018-0040-1

MLA:

Ludwig, Heinz, et al. "Prevention and management of adverse events of novel agents in multiple myeloma: A consensus of the European Myeloma Network." Leukemia 32.7 (2018): 1542-1560.

BibTeX: Download